evidence shows hrt decreased risks for type 2 diabetes
the north american menopause society (nams) released
updated guidelines for doctors over the summer, which helps cut through some of the narrative.
the nams guidance said there wasn’t enough evidence to recommend hrt as a preventive for dementia, a big point in this debate with dementia cases in women outnumbering men two-to-one. nams cited evidence that hrt does prevent bone loss and fracture, along with demonstrating decreased risks for everything from belly fat to colon cancer, type 2 diabetes, cardiovascular disease and all-cause mortality. (there is some evidence that estrogen is beneficial for skin, not enough for hair, nams said)
nams generally sticks to a “with symptoms” criteria for prescribing hormone therapy, which is backed up by the
u.s. preventive services task force, an independent and volunteer panel of national experts in disease prevention and evidence-based medicine, that does not recommend menopause hormone therapy for primary disease prevention in their latest systemic evidence review recently published in
jama network.
according to uspstf, “menopause typically occurs around age 50 years, and in the years following menopause, the rate of many chronic conditions, such as heart disease, stroke, diabetes, dementia, cancer, and bone fractures, increases. while aging may be the main cause, there has been some uncertainty about whether menopause also contributes to the development of these conditions. although menopausal hormone therapy can help treat menopausal symptoms, whether it helps prevent development of chronic medical conditions is unclear.”